Lilly posts $23B quarter as oral GLP-1 Foundayo trails Novo
Mounjaro brought in $9.94 billion and Zepbound $4.93 billion, while newly launched Foundayo managed $98 million in its first reported quarter.
The wire
- 01Eli Lilly reported second-quarter revenue of $23 billion, up 48%. Foundayo, approved April 1, logged $98 million, versus $355 million for Novo's oral Wegovy in its first quarter.
- 02Prescribers and telehealth operators tracking oral incretin supply see early evidence that patients are choosing Novo's oral semaglutide, which BMO attributes to efficacy over convenience.
- 03Lilly said its regulatory package for retatrutide is complete for obesity, obstructive sleep apnea and knee osteoarthritis pain, with an FDA filing planned for the first quarter of 2027.
From the source
Read at biospace.comLilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
Once again, Eli Lilly has delivered a massive earnings beat for the second quarter, with a 48% revenue increase to $23 billion. But the Indianapolis pharma’s oral GLP-1 Foundayo fell below expectations as patients lean toward Novo Nordisk’s rival product.
